04.09.10
Cephalon, Inc. has completed its acquisition of Mepha, a Swiss-based pharmaceutical company, for approximately $615.4 million. Mepha is now a wholly-owned subsidiary of Cephalon.
“We are proud to include Mepha as part of the Cephalon family. Mepha has a strong reputation for high quality products and services that deliver value to patients and healthcare professionals,” said Frank Baldino, Jr., Ph.D., chairman and chief executive officer of Cephalon. “This acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth."
Alain Aragues, executive vice president and president of Cephalon Europe, said, “We are pleased to add Mepha’s experience and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa. Cephalon intends to leverage Mepha’s brand recognition as the number one generics company in Switzerland and a prominent generic pharmaceutical company in many other markets.”
“We are proud to include Mepha as part of the Cephalon family. Mepha has a strong reputation for high quality products and services that deliver value to patients and healthcare professionals,” said Frank Baldino, Jr., Ph.D., chairman and chief executive officer of Cephalon. “This acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth."
Alain Aragues, executive vice president and president of Cephalon Europe, said, “We are pleased to add Mepha’s experience and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa. Cephalon intends to leverage Mepha’s brand recognition as the number one generics company in Switzerland and a prominent generic pharmaceutical company in many other markets.”